Anti-ntb-a antibodies and related compositions and methods

Abstract

Disclosed are antibodies, including antibody drug conjugates, that specifically bind to NTB-A. Also disclosed are methods for using the anti-NTB-A antibodies to detect or modulate activity of (e.g., inhibit proliferation of) an NTB-A-expressing cell, as well as for diagnoses or treatment of diseases or disorders (e.g., cancer) associated with NTB-A-expressing cells. Further disclosed is a method of treating multiple myeloma using an anti-NTB-A antibody drug conjugate, which optionally includes an anti-NTB-A antibody as disclosed herein.

What is claimed is: 
     
         1 . An isolated monoclonal antibody comprising VH and VL domains sharing at least 80% sequence identity to the amino acid sequences as respectively shown in residues 20-135 of SEQ ID NO:1 and residues 21-140 of SEQ ID NO:2. 
     
     
         2 . The antibody of  claim 1 , wherein the VH and VL domains share at least 90% sequence identity to the amino acid sequences as respectively shown in residues 20-135 of SEQ ID NO:1 and residues 21-140 of SEQ ID NO:2. 
     
     
         3 . The antibody of  claim 1 , wherein the VH and VL domains share at least 95% sequence identity to the amino acid sequences as respectively shown in residues 20-135 of SEQ ID NO:1 and residues 21-140 of SEQ ID NO:2. 
     
     
         4 . The antibody of  claim 1 , wherein the VH and VL domains share at least 99% sequence identity to the amino acid sequences as respectively shown in residues 20-135 of SEQ ID NO:1 and residues 21-140 of SEQ ID NO:2. 
     
     
         5 . The antibody of  claim 2 , wherein the antibody is chimeric or humanized. 
     
     
         6 . The antibody of  claim 1 , wherein the antibody is conjugated to a cytotoxic or cytostatic agent. 
     
     
         7 . The antibody of  claim 2 , wherein the antibody is conjugated to a cytotoxic or cytostatic agent. 
     
     
         8 . The antibody of  claim 3 , wherein the antibody is conjugated to a cytotoxic or cytostatic agent. 
     
     
         9 . The antibody of  claim 4 , wherein the antibody is conjugated to a cytotoxic or cytostatic agent. 
     
     
         10 . The antibody of  claim 5 , wherein the antibody is conjugated to a cytotoxic or cytostatic agent. 
     
     
         11 . A pharmaceutical composition comprising:
 the antibody of  claim 1 ; and   a pharmaceutically compatible ingredient.   
     
     
         12 . A pharmaceutical composition comprising:
 the antibody of  claim 2 ; and   a pharmaceutically compatible ingredient.   
     
     
         13 . A pharmaceutical composition comprising:
 the antibody of  claim 3 ; and   a pharmaceutically compatible ingredient.   
     
     
         14 . A pharmaceutical composition comprising:
 the antibody of  claim 4 ; and   a pharmaceutically compatible ingredient.   
     
     
         15 . A pharmaceutical composition comprising:
 the antibody of  claim 5 ; and   a pharmaceutically compatible ingredient.   
     
     
         16 . An antibody drug conjugate comprising an antibody conjugated to a cytotoxic agent, wherein the antibody comprises VH and VL domains sharing at least 80% sequence identity to the amino acid sequences as respectively shown in residues 20-135 of SEQ ID NO:1 and residues 21-140 of SEQ ID NO:2. 
     
     
         17 . An antibody drug conjugate comprising an antibody conjugated to a cytotoxic agent, wherein the antibody comprises VH and VL domains sharing at least 90% sequence identity to the amino acid sequences as respectively shown in residues 20-135 of SEQ ID NO:1 and residues 21-140 of SEQ ID NO:2. 
     
     
         18 . A pharmaceutical composition comprising the antibody drug conjugate of  claim 16 . 
     
     
         19 . A pharmaceutical composition comprising the antibody drug conjugate of  claim 17 .